No excuses TOG, think about it....if a pending deal was met (which very likely it was) with some milestones to be secured before moving forward which one would it be?
My top option would be the PS Targeting platform must be confirmed by another, reputable party and of course what did have way back when? Dr Jedd Wolchok enters the picture...hmmm, what better source of 3rd party approval could there neutrally exist ...that also brought forward Opdivo...etc
So now MSK Dr Wolchok speaks and it should not be a surprise to think that things are moving forward!
What is the worst case....Steve Worsley brought in Dr Wolchok on his own? Even better!....because no matter how you slice it...PS Targeting moving in on IO combos and all it takes is ONE greedy BP and I know they are all greedy so I sleep well tonight
It's awfully quiet out there....except for my leaf blower : )
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!